In addition to invasive methods such as liver biopsy, non-invasive scores such as the AST-to-platelet ratio index (APRI), fibrosis 4 (FIB-4) score, and ALT-to-AST ratio are also used to evaluate fibrosis in NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.